Zobrazeno 1 - 10
of 381
pro vyhledávání: '"Leufkens, H G M"'
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Kusynová, Z, Pauletti, G M, van den Ham, H A, Leufkens, H G M, Mantel-Teeuwisse, A K, Pharmacoepidemiology and Clinical Pharmacology, Afd Pharmacoepi & Clinical Pharmacology
Publikováno v:
Journal of Pharmaceutical Sciences, 111, 1318. John Wiley and Sons Inc.
Historical antecedents of pharmaceutical sciences are sound on product orientation based on (analytical) chemistry, drug delivery and basic pharmacology. Over the last decades we have seen a transition towards a stronger disease orientation. This rai
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::18e7370baceab8de871c30d408a8205a
https://doi.org/10.1016/j.xphs.2021.10.002
https://doi.org/10.1016/j.xphs.2021.10.002
Autor:
Narsai, K.1 (AUTHOR), Leufkens, H. G. M.1 (AUTHOR), Mantel-Teeuwisse, A. K.1 (AUTHOR) a.k.mantel@uu.nl
Publikováno v:
Journal of Pharmaceutical Policy & Practice. 4/1/2021, Vol. 14 Issue 1, p1-10. 10p.
Autor:
van der Linden, P. D., Sturkenboom, M. C. J. M., Herings, R. M. C., Leufkens, H. G. M., Stricker, B. H. Ch
Publikováno v:
BMJ: British Medical Journal, 2002 Jun 01. 324(7349), 1306-1307.
Externí odkaz:
https://www.jstor.org/stable/25228449
OBJECTIVE: Turkey's health reforms started in 2003 with providing changes in regulatory, financing, and healthcare services. Access to health care and pharmaceuticals increased rapidly, and this resulted with an increase in public pharmaceutical expe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od_______101::ef912f34aeb6ab21ccb80dc99c7a84d4
https://dspace.library.uu.nl/handle/1874/410955
https://dspace.library.uu.nl/handle/1874/410955
Autor:
Taghipour Bazargani, Y., Ugurlu, M, de Boer, A, Leufkens, H G M, Mantel-Teeuwisse, A K, Afd Pharmacoepi & Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology
Publikováno v:
BMC Cardiovascular Disorders, Vol 18, Iss 1, Pp 1-12 (2018)
BMC Cardiovascular Disorders
BMC Cardiovascular Disorders, 18(1). BioMed Central
BMC Cardiovascular Disorders
BMC Cardiovascular Disorders, 18(1). BioMed Central
Background The incidence and mortality of cardiovascular diseases (CVDs) in low and middle income countries (LMICs) have been increasing, while access to CVDs medicines is suboptimal. We assessed selection of essential medicines for the prevention an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::60d18cccf757c31a3f6032a52e254182
http://link.springer.com/article/10.1186/s12872-018-0858-5
http://link.springer.com/article/10.1186/s12872-018-0858-5
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Skovlund, E, Leufkens, H G M, Smyth, J F, Afd Pharmacoepi & Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology
Publikováno v:
European Journal of Cancer, 101, 69. Elsevier Ltd
European Journal of Cancer
European Journal of Cancer
Excitement about the dramatic increase in potential successful anticancer medicines in recent years is hampered by the high costs involved as well as the length of time traditional pathways take for regulatory approval. The translation of experimenta
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2d0659afe8b15984b0e049e556d6d895
https://dspace.library.uu.nl/handle/1874/376138
https://dspace.library.uu.nl/handle/1874/376138
Autor:
Coppens, D G M, de Wilde, S., Guchelaar, H.J., De Bruin, M L, Leufkens, H G M, Meij, Pauline, Hoekman, J, Afd Pharmacoepi & Clinical Pharmacology, Innovation and Sustainability, Innovation Studies, Pharmacoepidemiology and Clinical Pharmacology, Chemical Biology and Drug Discovery
Publikováno v:
Cytotherapy, 20(6), 769. Elsevier bedrijfsinformatie b.v.
Cytotherapy, 20(6), 769-778
Cytotherapy, 20(6), 769-778
There is a widely held expectation of clinical advance with the development of gene and cell-based therapies (GCTs). Yet, establishing benefits and risks is highly uncertain. We examine differences in decision-making for GCT approval between jurisdic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::88cffa8acc51b3efb2f67ccdfd4f6668
https://hdl.handle.net/1887/95568
https://hdl.handle.net/1887/95568